Zacks Research Forecasts Alkermes’ Q3 Earnings (NASDAQ:ALKS)

Alkermes plc (NASDAQ:ALKS) – Equities researchers at Zacks Research lowered their Q3 2026 earnings estimates for shares of Alkermes in a research note issued to investors on Wednesday, April 9th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.23 for the quarter, down from their previous forecast of $0.24. The consensus estimate for Alkermes’ current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes’ Q1 2027 earnings at $0.18 EPS.

Several other brokerages have also commented on ALKS. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Alkermes from $40.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, March 27th. HC Wainwright reaffirmed a “neutral” rating and issued a $46.00 price target on shares of Alkermes in a report on Thursday, February 13th. UBS Group upgraded Alkermes from a “sell” rating to a “neutral” rating and upped their price objective for the company from $21.00 to $38.00 in a research note on Tuesday, March 4th. StockNews.com raised Alkermes from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Finally, Royal Bank of Canada began coverage on Alkermes in a research note on Thursday, March 13th. They set a “sector perform” rating and a $40.00 price target for the company. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $38.50.

Alkermes Price Performance

NASDAQ ALKS opened at $27.00 on Friday. The stock has a market capitalization of $4.45 billion, a price-to-earnings ratio of 12.44, a PEG ratio of 2.20 and a beta of 0.39. The business’s fifty day moving average is $33.14 and its 200-day moving average is $30.45. Alkermes has a one year low of $22.90 and a one year high of $36.45.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ALKS. Avoro Capital Advisors LLC purchased a new stake in shares of Alkermes in the fourth quarter worth $70,462,000. Norges Bank purchased a new stake in shares of Alkermes in the 4th quarter valued at about $56,684,000. RTW Investments LP boosted its position in shares of Alkermes by 13.6% during the 4th quarter. RTW Investments LP now owns 7,557,835 shares of the company’s stock valued at $217,363,000 after acquiring an additional 903,802 shares during the last quarter. Nuveen Asset Management LLC boosted its position in shares of Alkermes by 109.5% during the 4th quarter. Nuveen Asset Management LLC now owns 1,659,821 shares of the company’s stock valued at $47,736,000 after acquiring an additional 867,492 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Alkermes by 147.4% during the fourth quarter. JPMorgan Chase & Co. now owns 889,472 shares of the company’s stock worth $25,581,000 after purchasing an additional 529,962 shares in the last quarter. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Craig C. Hopkinson sold 100,918 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $32.05, for a total transaction of $3,234,421.90. Following the sale, the executive vice president now owns 44,290 shares of the company’s stock, valued at approximately $1,419,494.50. This represents a 69.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.89% of the stock is owned by corporate insiders.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.